<p>Classical Hodgkin lymphoma is a&#xa0;malignant disease of the lymphatic system that can be differentiated into four stages according to the modified Ann Arbor classification and additionally regarding the presence of B&#xa0;symptoms. The German Hodgkin Study Group (GHSG) classification into early, intermediate, and advanced stages is used for further risk stratification. For early stages in patients ≤ 60&#xa0;years of age, combined radiochemotherapy consisting of two cycles of ABVD followed by involved-site radiotherapy (IS-RT) is the standard of care. In cases of persistent positron-emission tomography (PET) positivity, escalation to BEACOPPesc with a&#xa0;higher radiation dose is possible. Intermediate stages are currently treated with a&#xa0;combination of BEACOPPesc and ABVD, supplemented by radiotherapy in cases of PET-positive residual findings. These concepts can achieve cure rates of over 90% across early and intermediate stages. Despite the high therapeutic success, there is still room for optimization, particularly with regard to reducing acute and long-term toxicities. De-escalation strategies that forgo radiotherapy have so far shown disadvantages in terms of local control and survival. However, modern PET/CT-based treatment guidance opens up new possibilities for adjusting radiation volumes. It remains unclear whether irradiation of all initially affected areas is necessary in intermediate stages or whether focusing on PET-positive residues is sufficient; this issue is currently being addressed in a&#xa0;GHSG trial. In addition, the application of immune-based therapies is increasingly coming into focus. Studies such as NIVAHL and PREFER show promising results in terms of efficacy and tolerability, and immunotherapies could, in the long term, at least partially replace conventional chemotherapy. Overall, current research approaches aim to achieve greater individualization of treatment while maintaining high cure rates.</p>